Monthly Boluses Versus Daily Doses for Correcting Blood Vitamin D Deficit in Obese Children and Adolescents

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE3

Total Enrollment

68 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-12-04

Study Completion Date

2027-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Childhood obesity is one of the most serious public health challenges of the 21st century, with an increasing prevalence over time in developed countries. Overweight and obese children and adolescents are likely to remain so into adulthood and to develop chronic diseases at a young age, such as diabetes and cardiovascular disease.

Obese patients, whether adults or children, are likely to have low serum vitamin D levels due to sequestration and/or volumetric dilution of this fat-soluble vitamin in adipose tissue. Studies have established a link between vitamin D deficiency or insufficiency and chronic diseases such as hypertension, type 2 diabetes and other metabolic problems.

Determining physiological 25(OH)D levels to ensure optimal phosphocalcic metabolism and bone mineralisation requires the use of functional markers: parathyroid hormone (PTH) levels, assessment of the intestinal calcium absorption fraction, assessment of bone mineral density and bone mineral content using absorptiometry.

Vitamin D deficiency leads to malabsorption of calcium and phosphate in the digestive tract, with concentrations, especially of calcium, tending to fall in plasma, resulting in hypersecretion of PTH, which mobilises bone calcium to maintain subnormal blood calcium levels.

Each unit increase in BMI is associated with lower serum vitamin D concentrations: given these low concentrations in this population associated with the risk of developing pathologies, it is important to ensure adequate vitamin D supplementation.

The latest paediatric recommendations recommend, for children aged between 1 and 18 with vitamin D deficiency, a supplement of 2,000 IU/day for at least 6 weeks or a bolus of 50,000 IU once a week for at least 6 weeks.

There are different dosage regimens for the replacement of vitamin D deficiency depending on the country: there is a lack of data on the appropriate dosage and administration regimens for vitamin D supplementation in cases of deficiency, particularly in obese children and adolescents. A prospective, randomised clinical trial will make it possible to define the vitamin D supplementation regimen best suited to increasing serum vitamin D levels in these children and adolescents suffering from obesity.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy of Vitamin D Supplementation in Obese Children

NCT02956408

Obesity, Pediatric Obesity, Childhood Obesity, Morbid +1 more

COMPLETED NA

Vitamin D Intervention in Young Adults With Severe Childhood-onset Obesity

NCT02549326

Obesity

COMPLETED NA

Vitamin D Deficiency and Low Bone Mineral Content in Children

NCT00756899

Vitamin D Deficiency Obesity

COMPLETED

Vitamin D Supplementation Requirement in Obese Subjects

NCT00996866

Vitamin D Deficiency

TERMINATED NA

Vitamin D Supplementation in Vitamin D Deficient Obese Children During Weight-loss Program

NCT02828228

Obesity

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity, Childhood

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Monthly bolus arm

Group Type EXPERIMENTAL

Monthly bolus of cholecalciferol per os

Intervention Type DRUG

Bolus therapy: first 50 000 IU and a second 50 IU after 6 weeks

Daily arm

Group Type EXPERIMENTAL

Daily dose of cholecalciferol per os

Intervention Type DRUG

Daily substitution, 1200 IU per day (4 drops), for 3 months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Monthly bolus of cholecalciferol per os

Bolus therapy: first 50 000 IU and a second 50 IU after 6 weeks

Intervention Type DRUG

Daily dose of cholecalciferol per os

Daily substitution, 1200 IU per day (4 drops), for 3 months

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged between 5 to 18 year-old
* Being obese (BMI \>97th percentile, \> IOTF 30, for age and gender using the WHO references)
* Patients (parents) having given their informed consent
* Patient having insurance from the national health system

Exclusion Criteria

Children will be excluded from the study if:

* Symptomatic vitamin D deficiency (tetany, muscular hypotonia, hypocalcaemic seizure)
* Vitamin D supplementation in the 3 months preceding the inclusion visit (V1)
* Signs of rickets at the X-ray (osteopenia and cortical thinning of the long bones, stress fractures, and metaphyseal widening and fraying)
* Chronic disease such as granulomatous conditions, Williams syndrome, or hypothyroidism predisposing to hypocalcaemia or in case of hypercalcaemia (calcium \> 2.65 mmol/L), liver/kidney disease, malabsorption diseases;
* Hypercalciuria (urinary Calcium/Creatinine \> 0.7 mmol/mmol), calcium nephrolithiasis, hypervitaminosis D (25-(OH)D \> 250 nmol/L); nephrocalcinosis;
* Ongoing treatment with anticonvulsants/barbiturates or steroids which increase the catabolism of 25(OH)D;
* Ongoing treatment with thiazides diuretics which reduce urinary excretion of calcium;
* Contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to class of drugs or the investigational product;
* Pregnancy, breastfeeding;
* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant;
* Simultaneous enrolment to another study which could influence the results of the current study;
* Patient under legal protection or deprived of liberty.

Minimum Eligible Age

5 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No